DALLAS, April 14, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring GTx Inc. (Nasdaq:GTXI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at:
GTx Inc. (GTXI), a biopharmaceutical company, engages in the discovery, development and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer and the side effects of anticancer therapy, cancer supportive care and other serious medical conditions. The Company's newest product candidate is Capesaris (GTx-758), which is a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer. GTx-758 has the potential to achieve medical castration without causing bone loss or hot flashes. It is developing Ostarine (GTx-024) and other selective androgen receptor modulators (SARMs) for the prevention and treatment of muscle loss in patients with cancer and for other muscle wasting diseases. Additionally, GTXI is developing toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy for prostate cancer.
This newsletter has been helping traders make great investment decisions on GTXI; click here for a 25% discount offer.
In the report, the analyst notes:
"GTXI ticked higher Wednesday after Citigroup upgraded the stock from Hold to Buy. The price target was also raised from $4 to $8. GTX gained $0.93, or 33.82%, to close the session at $3.68 on unusual volume of 3.83 million shares traded on the day. It reached a day's high of $4.18 and a day's low of $3.05."
"GTXI met with the FDA in February 2011 and confirmed that the primary endpoint acceptable for approval for this indication is total testosterone levels (achieve and maintain serum total testosterone levels less than 50ng/dL). GTXI will launch a Phase IIb study for Capesaris in the second quarter of this year, evaluating the drug compared to Lupron (leuprolide acetate), a luteinizing hormone releasing hormone (HRH) agonist for first line treatment in men with advanced prostate cancer."
To read the entire report visit:
See what investors are saying about GTXI at
Get breaking news on GTXI at
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: Brian Johnson firstname.lastname@example.org 1-888-307-2850